SMPD3 and Alzheimer disease: Inhibition of nSMase2 has been identified as a therapeutic target for several diseases, including neurological disorders such as AD, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease (for review, see [8]).